Clinical Trial Update: EZN-2279 in Patients With ADA-SCID [Phase 3]

View source ↗

Summary

Phase 3 trial update for EZN-2279 in ADA-SCID has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ada-scid
• Adenosine Deaminase Deficiency
• Combined Immunodeficiency

Drugs mentioned

• EZN-2279

Snippet

Sponsor: Leadiant Biosciences, Inc. | Conditions: ADA-SCID, Adenosine Deaminase Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2020-04-16